Oppenheimer initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a report published on Thursday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $48.00 price target on the stock.
A number of other equities analysts also recently commented on DNTH. Cantor Fitzgerald assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They set an overweight rating for the company. Wedbush lowered their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an outperform rating for the company in a research report on Friday, August 9th. Lifesci Capital raised Dianthus Therapeutics to a strong-buy rating in a research report on Tuesday, June 11th. Baird R W raised Dianthus Therapeutics to a strong-buy rating in a report on Friday, July 26th. Finally, HC Wainwright reiterated a buy rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Nine investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Buy and an average target price of $45.13.
Check Out Our Latest Stock Report on DNTH
Dianthus Therapeutics Trading Up 2.0 %
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The firm had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. On average, equities analysts forecast that Dianthus Therapeutics will post -2.32 EPS for the current fiscal year.
Institutional Trading of Dianthus Therapeutics
A number of large investors have recently bought and sold shares of DNTH. SG Americas Securities LLC purchased a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $112,000. The Manufacturers Life Insurance Company acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at about $236,000. WINTON GROUP Ltd purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at approximately $265,000. Point72 DIFC Ltd purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at approximately $334,000. Finally, Virtu Financial LLC acquired a new stake in Dianthus Therapeutics during the 1st quarter worth approximately $390,000. Institutional investors and hedge funds own 47.53% of the company’s stock.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Recommended Stories
- Five stocks we like better than Dianthus Therapeutics
- Stock Average Calculator
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- Learn Technical Analysis Skills to Master the Stock Market
- MarketBeat Week in Review – 9/30 – 10/4
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.